(Updated - November 2, 2016 10:38 AM EDT)

JPMorgan downgraded Intersect ENT (NASDAQ: XENT) from Overweight to Neutral with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change Downgrades

Leerink Partners Cuts Price Target on Intersect ENT (XENT) to $14; Reiterates Outperform November 3, 2016 7:41 AM